Using stem cells to treat heart attacks
Therapeutic Use of Angiopoietin-Primed Autologous Peripheral Blood Stem Cell in Myocardial Infarction
This study is testing if using a patient's own stem cells can help their heart heal better after a heart attack.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 19 Years to 80 Years |
| Sex | All |
| Sponsor | Seoul National Hospital Government |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06364150 on ClinicalTrials.gov |
What this trial studies
This study evaluates the safety and efficacy of using autologous peripheral blood stem cells, primed with angiopoietin 1, for myocardial regeneration in patients who have experienced an acute myocardial infarction. Participants will undergo standard percutaneous coronary intervention followed by mobilization of their stem cells using G-CSF and EPO. The mobilized stem cells will be collected and primed ex-vivo before being injected into the affected coronary artery. The goal is to assess whether this innovative approach can improve heart function after a heart attack.
Who should consider this trial
Good fit: Ideal candidates are adults aged 19 to 80 who have been diagnosed with an acute myocardial infarction within the last four weeks and have undergone successful coronary intervention.
Not a fit: Patients with uncontrolled heart failure, active malignancies, or significant non-cardiac comorbidities may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this treatment could enhance heart recovery and improve outcomes for patients who have suffered a heart attack.
How similar studies have performed: Other studies have shown promise in using stem cell therapies for cardiac repair, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Male and female aged ≥19 years and ≤ 80 years * 2\. A clinical diagnosis of acute myocardial infarction within 4 weeks from randomization * 3\. Successful percutaneous coronary intervention to the target lesion (TIMI flow grade 3 and residual stenosis \<30% at the target lesion) with a drug-eluting stent and/or drug-eluting balloon * 4\. Agreement to give written informed consent. Exclusion Criteria: 1. Patients with uncontrolled heart failure (Killip class ≥ grade 2, or left ventricular ejection fraction \<20%) 2. Patients with uncontrolled chest pain due to ischemia 3. Patients with uncontrolled arrythmia 4. Active malignancy, or incompletely treated malignancy 5. Active infectious disease 6. Uncontrolled hematologic disease, including coagulopathy or bleeding diathesis 7. Presence of non-cardiac comorbidity with life expectancy ≤1 year from randomization 8. Females with childbearing potential or breast-feeding 9. Refusal to give written informed consent 10. Other conditions that may result in protocol non-compliance by the committees
Where this trial is running
Seoul
- Seoul National University Hospital — Seoul, South Korea (Recruiting)
Study contacts
- Principal investigator: Hyun Jai Cho, MD — Seoul National University Hospital
- Study coordinator: Jeehoon Kang, MD
- Email: medikang@gmail.com
- Phone: +821024162406
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.